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Parathyroidhormone-relatedprotein(PTHrP)hasanumberofcancer-relatedactions.Whilebestknownforcausinghypercalcemia
of malignancy, it also has eﬀects on cancer cell growth, apoptosis, and angiogenesis. Studying the actions of PTHrP in human
cancer is complicated because there are three isoforms and many derived peptides. Several peptides are biologically active at known
or presumed cell surface receptors; in addition, the PTHrP-derived molecules can exert eﬀects at the cell nucleus. To address this
complexity, we studied gene expression in a DU 145 prostate cancer cell line that was stably transfected with control vector, PTHrP
1-173 and PTHrP 33-173. With this model, regulatory eﬀects of the amino-terminal portion of PTHrP would result only from
transduction with the full-length molecule, while eﬀects pertaining to distal sequences would be evident with either construct.
Analysis of the expression proﬁles by microarrays demonstrated nonoverlapping groups of diﬀerentially expressed genes. Amino-
terminal PTHrP aﬀected groups of genes involved in apoptosis, prostaglandin and sex steroid metabolism, cell-matrix interactions,
andcelldiﬀerentiation,whilePTHrP33-173causedsubstantialincreasesinMHCclassIantigenexpression.Thisworkdemonstrates
the distinct biological actions of the amino-terminus compared to distal mid-molecule or carboxy-terminal sequences of PTHrP in
prostate carcinoma cells and provides targets for further study of the malignant process.
INTRODUCTION
Parathyroid hormone-related protein (PTHrP) is best
known as the factor responsible for humoral hypercal-
cemia of malignancy, but it exerts other important eﬀects
in cancers and cancer cells. Among them are regulations
of cell growth, apoptosis, cytokine production, and an-
giogenesis [1, 2, 3, 4]. Given these properties, it is not sur-
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prising that PTHrP contributes to cancer progression and
metastasis.PTHrPhasbeenfoundtostimulatethegrowth
of tumors in several models of human cancer [5, 6, 7]a n d
PTHrP expression is associated with an increased inci-
dence of metastases and early mortality in cancer patients
with hypercalcemia [8].
ThecomplexbiologyofPTHrPinvolvesdiversemech-
anisms for its eﬀects. PTHrP is a secretory protein that
is processed and acts through both paracrine and au-
tocrine pathways by binding at cell surface receptors. The
amino-terminus of PTHrP, PTHrP 1-32, acts through
the type I PTH/PTHrP receptor (PTH1R) [9] that also
binds parathyroid hormone. Ligation of PTH1R is in-
volved in the hypercalcemic sequelae of cancer, and can
also mediate various growth-related eﬀects. In addition,
posttranslational processing releases non-amino forms of
PTHrP that exert biological actions. For example, PTHrP354 I. Tsigelny et al 2005:4 (2005)
38-94 promotes placental calcium transfer [10], PTHrP
67-86 inhibits growth of breast carcinoma cells [11]a n d
sensitizes lung alveolar epithelial cells to apoptosis [12],
peptides included in PTHrP 107-141 inhibit osteoclast
function [13], and PTHrP 140-173 regulates metabolism
of orthophosphate by articular chondrocytes and protects
lung cancer cells from apoptosis [14]. Cell surface re-
ceptors that mediate the eﬀects of non-amino-terminal
peptides have been postulated but have yet to be identi-
ﬁed. PTHrP possesses a nuclear localizing sequence and
can enter the nucleus to exert eﬀects through an intra-
cellular or intracrine mechanism [15]. The intracrine ac-
tions of PTHrP are frequently growth, or apoptosis re-
lated [2, 16]. Thus, the eﬀects of PTHrP in an individual
tissue can be regulated by expression of PTH1R and re-
ceptors yet to be discovered, by the cellular processing ap-
paratus, and by nuclear localization and intracrine path-
ways.
The goal of this study was to use microarray technol-
ogytoidentifygenesregulatedbyPTHrPinaprostatecar-
cinoma cell line. We compared gene expression proﬁles
between cells transfected with control vector, PTHrP 1-
173 and PTHrP 33-173. This strategy provided a means
to distinguish between the eﬀects of amino-terminal
PTHrP and the rest of the molecule. For example, a
gene that was upregulated only by PTHrP 1-32 would
be upregulated by PTHrP 1-173 and not by PTHrP 33-
173, while one that was under the control of a region
within PTHrP 33-173 would be upregulated by both con-
structs.
MATERIALS AND METHODS
Cellculture
The DU 145 human prostate cancer cell line [17]w a s
obtained from American Type Culture Collection (Man-
assas, Va) and was grown in monolayer in RPMI 1640
media (Mediatech Inc, Herndon, Va) supplemented with
5% fetal bovine serum (Gemini Bio-Products, Woodland,
Calif) at 37◦C in a humidiﬁed incubator with 95% air, 5%
CO2. This cell line was selected because it has low consti-
tutive PTHrP expression.
Stabletransfection
PreproPTHrP 1-173 and preproPTHrP 33-173 con-
structsweredirectionallysubclonedinthepCI-neomam-
malianexpressionvectorthatutilizes thecytomegalovirus
promoterforrobustexpressionofthetransgene(Promega
Corp, Madison, Wis). The ﬁdelities of the plasmids were
conﬁrmed by DNA sequencing and site-speciﬁc PTHrP
immunoassays of cells transduced with the constructs
[18]. The pCI-neo vector contains a neomycin resistance
cassette that allows G418 selection of stable clones of
DU 145 cells that express preproPTHrP 1-173 and pre-
proPTHrP 33-173. The prepro-forms were used to facili-
tate PTHrP secretion [19].
Microarrayanalysis
T h ep r o s t a t ec a n c e rc e l l sw e r es e e d e da tac o n ﬂ u e n c y
of 75% in 100 mm tissue culture dishes at 37◦Ci nah u -
midiﬁed incubator with an atmosphere of 5% CO2.T h e
next day, the media were aspirated from the dishes, the
cells were washed with PBS, and serum-free medium was
added to the cells for 18h. The RNA was harvested by
the RNeasy kit (Qiagen, Valencia, Cailf) protocol, as per
manufacturer’s recommendations. cDNAs were synthe-
sized from the total RNA using a reverse transcriptase
enzyme and biotin-labeled cRNAs were made using an
RNA transcript labeling kit. The biotin-labeled RNA frag-
ments were next hybridized to the probe array of a U133A
Aﬀymetrix GeneChip (Santa Clara, Cailf), which con-
tains 19571 probe sets corresponding to approximately
16000 separate genes. The hybridized array was stained
with a streptavidin phycoerythrin conjugate and scanned
by a GeneChip Scanner. The amount of light emitted at
570nm was proportional to the bound target at each lo-
cation on the probe array.
Six experiments were performed: two with the cells
transfectedonlywiththepCI-neocontrolvector,twowith
the cells transfected by preproPTHrP 1-173, and two with
cells transfected by preproPTHrP 33-173.
Bioinformaticanalysis
Initial signal preprocessing was performed as recom-
mended by Aﬀymetrix. We used the Aﬀymetrix software
normalization tools to enable the comparison of results
from diﬀerent chips. We restricted the analyses to the data
for those genes in which two members of the experimen-
tal group (vector, PTHrP 1-173, PTHrP 33-173) each had
“P” (present) detection levels. Gene expression values for
the cells transfected by PTHrP were normalized to the av-
erage expression levels in the proﬁles for the cells trans-
fected with control vector. To provide a biological frame-
workfortheobservedchangesingeneexpression,weana-
lyzed the genes that were up- or downregulated by PTHrP
in terms of their biological process, molecular function,
cell compartment, and signaling pathway, utilizing the
terms established by the Gene Ontology (GO) Consor-
tium [20]. We considered a signiﬁcant change in gene
expression after PTHrP transfection to be an increase of
more than twofold or a decrease of more than 40% com-
pared to cells transfected with vector control. We also in-
cludedgenesthatwereupregulatedbyafactorof1.75-fold
if they were closely clustered in one chromosomal loca-
tion and shared gene ontology terms with other upregu-
lated genes in that locus. A lower threshold was accepted
in these cases because the location and ontology data rep-
resented additional information supporting a diﬀerential
eﬀect of PTHrP on gene expression.
Criteriausedtodeﬁnecoherent
expressionchromosomeclusters
Gene Ontology uses the following classes to group
genes: molecular function (MF), cell compartment (CC),2005:4 (2005) PTHrP and Diﬀerential Gene Expression in Prostate Cancer 355
biological process (BP), and signaling pathway (PW). We
consider the cluster of genes on any chromosome as a
“coherent expression chromosome cluster (CECC)” when
a cluster of genes in a chromosome express together in
a common pattern that is consistent with the following
rules:
(1) all genes of this region are over- or underexpressed
d u et oe x p o s u r et oac o m m o nf a c t o r( i no u rc a s e
PTHrP);
(2) the genes are located in the same chromosomal
banding region (or in the neighboring localization
in two adjacent chromosome band regions);
(3) the genes ﬂanking the CECC have similar ontologi-
cal deﬁnition(s) (MF or CC).
All of the genes that are regulated by PTHrP and lie
between the two ﬂanking genes having similar GO deﬁni-
tions are considered members of the CECC.
Examples of such analysis appear below.
( a )C E C Co nc h r o m o s o m e6( Figure 2). The CECC is
located on the boundary of the bands 6.22 and 6.23 and
Butyrophilin CC2
ZNF305 (Zn-binding) CC1 MF1
HLA-F CC2 MF2 BP2
HLA-G CC2 MF2 BP2
HLA-A CC2 MF2 BP2
HLA-C CC2 MF2 BP2
HLA-B CC2 MF2 BP2
DDR1 CC2
Ring protein (Zn-binding) CC1 MF1
6p21
6p22
where CC1—nuclear localization, CC2—plasma mem-
brane localization, MF1—Zn binding, MF2—MHC class
Ir e c e p t o r s ,B P 2—immune response.
Here two separate CECCs appear to overlap each
otherﬂankedbyRingproteinandZNF305inonecaseand
by DDR1 and butyrophilin in the other. For the simplicity
of explanation, we have considered it as a single CECC.
(b) CECC1 on chromosome 16 (Figure 3).
NOL3 nucleolar protein CC1
PARD6A CC2
FLJ CC1 MF1
cadherin 1-P CC3 MF3 BP3
cadherin 1-E CC3 MF3 BP3
Cytochrome B5 CC2
SF3B3 splicing factor CC1 MF1
16p22
where CC1—nuclear localization, CC2—membrane lo-
calization, CC3—integral to membrane, MF1—DNA
binding,MF3—celladhesion,calciumionbinding,BP3—
cell adhesion.
A group of genes within the CECC are not related by
ontology to the ﬂanking genes, but per deﬁnition are con-
sidered members of the CECC. They most probably are
“switched on” by the same transcription activation factor
as the rest of CECC.
RESULTS
Transfection of DU 145 cells with PTHrP 1-173 and
PTHrP 33-173 expression plasmids increased the con-
centration of immunoreactive PTHrP that the cells re-
leased into the media by two- to ﬁvefold compared to
the amount secreted by cells transfected with vector. In
prostate cancer cells, 17 genes were upregulated twofold
or more by transfection with PTHrP 1-173 compared
to vector control but the same genes were unaﬀected by
the PTHrP 33-173 construct (Table 1). The most striking
change involved three members of the aldo-keto reduc-
tase family, C1, C2, and C3, which were increased from 8-
to 13-fold. This ﬁnding is notable because only 9 of the
genes probed by the U133A chip, approximately 0.04% of
the total, code for proteins with aldo-keto reductase ac-
tivity, yet 19% of the genes that had GO terms and were
upregulated by PTHrP 1-173 fell into that category. The
aldo-keto reductase genes are all located on chromosome
10p15 (Figure 1). The PTHrP 1-173-upregulated group
also included four genes involved in cell adhesion or cy-
toskeletal organization: cysteine-rich with EGF-like do-
mains 1 (CRELD1), syndecan 2, nebulette, and junction
plakoglobin. Finally, four genes out of the collection of 17
have been implicated in growth and/or apoptosis regula-
tion, transforming growth factor β2 (TGFB2), interferon
induced protein 16 (IFI16), caspase 10 (CASP10), and p8
protein (candidate of metastasis) (P8).
The full-length PTHrP molecule downregulated 22
g e n e st ol e s st h a n4 0 %o fc o n t r o ll e v e l s .T h e s eg e n e s
were not aﬀected by the construct lacking the amino-
terminal portion of PTHrP. The group was notable for
a large number of genes involved in development or dif-
ferentiation: pre-B-cell leukemia transcription factor 1
(PBX1), kinesin family member 5C (KIF5C), somato-
statin (SST), diphtheria toxin receptor (DTR), gap junc-
tion protein alpha 1 (GJA1), connective tissue growth
factor (CTGF), adipose diﬀerentiation-related protein
(ADFP), myotubularin-related protein 2 (MTMR2), high
mobility group AT-hook 2, and MAGEA8. PBX1 and
HMGA2 mediate transcription factor-promoter interac-
tions, and PBX1 and SST have interactions with Hox
proteins. Several downregulated genes, including tumor
necrosis factor receptor superfamily 25 (TNFRSF25),
SST, diphtheria toxin receptor DTR, intestinal cell kinase
(ICK), GJA1, ADFP, MTMR2, and interleukin 23 (IL23A)
are involved in signal transduction.356 I. Tsigelny et al 2005:4 (2005)
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Cohernt expression cluster on chromosome 10 (10p15)
Figure 1. Cluster of functionally similar genes induced by PTHrP 1-32 on chromosome 10. RNA from DU 145 prostate carcinoma
cells that were stably transfected with PTHrP 1-173 (in gray), PTHrP 33-173 (in black), or vector was probed with an Aﬀymetrix
U133A array and analyzed for diﬀerential changes in gene expression between vector and PTHrP-transfected cells. The graph demon-
strates a coherent expression cluster, a chromosomal region containing functionally related coregulated genes. The ordinate shows
mRNA levels from the PTHrP-transfected cells expressed as a % of the levels measured in the vector-transfected cells. In this ex-
ample from chromosome 10p15, the genes are members of the aldo-keto reductase family that are involved in the metabolism of
prostaglandin D2 to prostaglandin F2a and in conversion of androgens to inactive forms. PTHrP 1-173 transfection caused an (8–
13)-fold increase in levels for the three genes.
25 27 29 31 33 35 37 ×106
Position on chromosome
50
100
150
200
250
300
350
400
E
x
p
r
e
s
s
i
o
n
d
i
ﬀ
e
r
e
n
c
e
H
2
B
h
i
s
t
o
n
e
B
u
t
y
r
o
p
h
i
l
i
n
Z
i
n
c
ﬁ
n
g
e
r
p
r
o
t
e
i
n
3
0
5
H
L
A
-
F
H
L
A
-
A
H
L
A
-
G
D
i
s
c
o
i
d
i
n
d
o
m
a
i
n
r
e
c
e
p
t
o
r
H
L
A
-
B
H
L
A
-
C
M
I
C
A
D
D
A
H
H
U
M
M
H
C
W
1
A
P
r
o
t
e
a
s
o
m
e
R
i
n
g
ﬁ
n
g
e
r
p
r
o
t
e
i
n
1
H
o
m
o
s
a
p
i
e
n
s
c
l
o
n
e
2
3
8
7
2
m
R
N
A
T
r
a
n
s
c
r
i
p
t
i
o
n
f
a
c
t
o
r
e
t
s
Cohernt expression cluster 2 on chromosome 6 (6p21,6p22)
Figure 2. Functionally coherent expression induced by PTHrP 33-173. This graph represents data for chromosome 6p21-22 from the
same experiment described in Figure 1. HLA-A, HLA-B, HLA-C, HLA-F, and HLA-F are all upregulated by PTHrP 33-173 in black
(gray PTHrP 1-173). Ring ﬁnger protein 1 and two proteasome beta subunits, which are also upregulated, may work with the HLA
antigens in a common pathway, since the proteasome is responsible for processing intracellular proteins to be presented on the cell
surface with the HLA antigens.
The number of genes regulated by the non-amino-
terminal portion of PTHrP was much larger than the
number aﬀected by amino-terminal PTHrP. PTHrP 33-
173 upregulated 253 genes in DU 145 cells to levels >
200% of control cells and downregulated 103 genes. Table
2 presents a sampling of genes identiﬁed and organized by
function. Several human leukocyte antigen (HLA) class
I molecules, all located in close proximity on chromo-
some 6p21 (Figure2),wereupregulatedbyPTHrP33-173
twofold or more. Interestingly, the 6p21-22 region also2005:4 (2005) PTHrP and Diﬀerential Gene Expression in Prostate Cancer 357
Table 1. Genes regulated by PTHrP 1-173 but unaﬀected by PTHrP 33-173.
Gene Unigene no Region
Expression with
PTHrP 1-173
transfection∗(%)
Upregulated to>200%o fc o n tr o l
Transforming growth factor, beta 2 Hs.169300 1q41 265
Interferon, gamma-inducible protein 16 370873 1q23 264
ALL1-fused gene from chromosome 1q 75823 1q21 271
Interferon-induced protein 44 82316 1p31 344
Caspase 10, apoptosis-related cysteine protease 5353 2q33 255
Zinc ﬁnger protein 288 436987 3q13 281
Cysteine-rich with EGF-like domains 1 9383 3p25 253
I factor (complement) 312485 4q25 494
Rab coupling protein 96125 8p11 292
Syndecan 2 1501 8q22 253
Aldo-keto reductase family 1, member C1 306098 10p15 991
Aldo-keto reductase family 1, member C2 201967 10p15 1328
Aldo-keto reductase family 1, member C3 78183 10p15 785
Hypothetical protein FLJ12616 287537 10q26 260
Nebulette 5025 10p12 277
p8 protein (candidate of metastasis 1) 418692 16p11 263
Junction plakoglobin 2340 17q21 298
Downregulated to<40%o fc o ntr ol
Tumor necrosis factor receptor superfamily, member 25 299558 1p36 20
Pre-B-cell leukemia transcription factor 1 40822 1q23 23
Kinesin family member 5C 6641 2q23 39
Butyrylcholinesterase 422857 3q26 21
Somatostatin 12409 3q28 31
Hypothetical protein FLJ23235 211501 4p14 34
Hypothetical protein FLJ23548 22895 4q26 39
Hypothetical protein DKFZp434N1235 149030 4q28 12
Potassium intermediate/small conductance
Calcium-activated channel, subfamily N, member 2 98280 5q22 16
Lysyl oxidase 102267 5q23 32
Diphtheria toxin receptor 799 5q23 36
Intestinal cell kinase 417022 6p12 37
Connexin 43 74471 6q21 29
Connective tissue growth factor 410037 6q23 33
Adipose diﬀerentiation-related protein 3416 9p22 34
Myotubularin-related protein 2 181326 11q22 38
Interleukin 23, alpha subunit p19 98309 12q13 33
High mobility group AT-hook 1 57301 6p21 36
Heat shock 105kD 36927 13q12 36
Glycine amidinotransferase 75335 15q15 39
Ubiquitin-like 5 386532 19p13 16
Melanoma antigen, family A, 8 37109 Xq28 39
*Expression is presented as a % of the expression by the vector-transfected control cells.
includes three upregulated genes coding for a ring ﬁnger
protein (RING1) and two components of the proteasome,
beta subunits 8 and 9 (PSMB8,PSMB9). These proteins
are functionally related to the major histocompatibility
complex proteins because the proteasome processes pep-
tides for presentation with HLA I proteins [21]. Fur-
thermore, RING1 is involved in monoubiquitination of
proteins targeted for proteasomal processing [22]. Thus,358 I. Tsigelny et al 2005:4 (2005)
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Figure 3. Functionally coherent expression induced by PTHrP 33-173. This graph represents data for chromosome 6 from the same
experimentdescribedinFigure1.AllproteinsareallupregulatedbyPTHrP33-173inblack (grayPTHrP1-173).Coherentexpression
cluster 1 on chromosome 16 (p22). E-cadherin (CDH1) and P-cadherin (CDH3) are both involved in cell-cell interaction and lie
within a 0.15-megabase region on chromosome 16p22. PTHrP 33-173 downregulated several genes coding for proteins involved in
cell-matrix or cytoskeletal interaction and also decreased expression of DICRI, a Dcr-1 homolog. DICER1 codes for a ribonuclease
that produces active small RNA components involved in repressing gene expression.
6p21-22 contains an amplicon of genes with related func-
tional properties that share responsiveness to PTHrP 33-
173, a feature we term a coherent expression cluster.
Chromosome 16 (Figure 3) also contains a coherent ex-
pression cluster for PTHrP 33-173 consisting of a pair
of genes. E-cadherin (CDH1) and P-cadherin (CDH3),
which are both involved in cell-cell interaction [23, 24,
25], lie within a 0.15 megabase region on chromosome
16p22. PTHrP 33-173 downregulated several genes cod-
ing for proteins involved in cell-matrix or cytoskeletal in-
teraction and also decreased expression of DICRI, a Dcr-1
homolog. DICER1 codes for a ribonuclease that produces
active small RNA components involved in repressing gene
expression [26].
PTHrP regulated a total of 245 annotated genes in
DU 145 cells. Of this group, 219 were found in CECCs
and 26 were not. Other investigators have estimated that
20% of the expressed annotated genes on the Aﬀymetrix
U133A chip may fall into functional clusters [27]. Thus,
thenumberofPTHrP-regulatedgenesincludedinCECCs
was much greater than expected on the basis of chance
alone (Chi square P<. 0001).
DISCUSSION
This work utilized a novel approach to microarray
analysis to demonstrate distinct pathway- or process-spe-
ciﬁc diﬀerences in the pattern of gene expression induced
by amino-terminal versus distal sequences of PTHrP. We
compared microarray data from human prostate car-
cinoma cells transfected with full-length PTHrP 1-173
versus cells expressing a non-amino-terminal peptide,
PTHrP33-173,whichlackstheamino-terminalsequence.
We have attempted to generate smaller PTHrP peptides
on the order of PTHrP 1-32 with transfected expression
plasmids. However, transfection with these plasmids does
not appear to generate immunoreactive PTHrP, presum-
ably because the molecules are too short to transverse
the endoplasmic reticulum [19]. With the comparison
between PTHrP 1-173 and PTHrP 33-173, a change in
functionthatdependedonamino-terminalPTHrPwould
be observed only after transduction with PTHrP 1-173,
while eﬀects due to distal PTHrP sequences, common
to both PTHrP forms, would be apparent with either
construct. Amino-terminal PTHrP comprises PTHrP 1-
32, a physiologic ligand for the receptor shared with the
amino-terminus of PTH. The distal region contains mid-
molecule and carboxy-terminal sequences that also ex-
ert biologic activity, but have no known receptors [28].
The mid-molecule region also contains a nuclear local-
izing sequence (NLS) at residues 87–106 and an ad-
jacent sequence at amino acids 107–139 that are im-
portant for intracrine eﬀects [15, 29]. The sequence of
PTHrP 65–171 is 39% homologous to CHD-4, a nu-
clear DNA binding protein. Structural studies are ongo-
ing to evaluate whether a DNA binding function with
this region is important for PTHrP intracrine eﬀects.
Thus, PTHrP could inﬂuence prostate cancer pathology
through multiple mechanisms; these mechanisms could
be modulated by protein processing, changes in secre-
tory pattern, receptor expression, and nuclear localiza-
tion.
We found that regulation of genes in several path-
ways and biologic processes varied in a manner depen-
dent on speciﬁc PTHrP regions. Amino-terminal PTHrP
increased mRNA levels for several aldo-keto reductase
(AKR) enzymes (Table 1), genes related to cell adhesion
and cytoskeleton, and genes regulating growth and/or
apoptosis, eﬀects not observed with cells transfected with
thecutversionofPTHrP.Inaddition,theamino-terminal2005:4 (2005) PTHrP and Diﬀerential Gene Expression in Prostate Cancer 359
Table 2. Representative genes regulated by PTHrP 33-173.
Gene Unigene no
Expression with
PTHrP 33-173
transfection∗(%)
Upregulated genes
Class1 major histocompatibilitycomplex proteins
HLA-A Hs. 181 244 6p21 224
HLA-B Hs. 77 961 6p21 200
HLA-C Hs. 274 485 6p21 201
HLA-F Hs. 411 958 6p21 180
HLA-G Hs. 512 152 6p21 242
Proteasome-relatedproteins
Proteasome (prosome, macropain) subunit, beta type, 8 Hs. 180 062 6p21 358
Proteasome (prosome, macropain) subunit, beta type, 9 Hs. 381 081 6p21 318
Ring ﬁnger protein 1, RING1 Hs. 202 430 6p21 249
Proteinsmediatingcell-cell interactions
E-cadherin, CDH1 Hs. 194 657 16q22 334
P-cadherin, CDH3 Hs. 191 842 16q22 229
Arachidonicacid pathway proteins
Glutathione peroxidase 1, GPX1 Hs. 76 686 3p21 200
Glutathione peroxidase 3, GPX3 Hs. 386 793 5q23 718
Nuclear proteins
Basic leucine nuclear zipper factor Jem-1, BLZF1 Hs. 444 697 1q24 221
Kruppel-like factor 3, KLF3 Hs. 145 754 4p14 197
Zinc ﬁnger protein 305, ZNF305 Hs. 134 816 6p22 229
Downregulated genes
Cell-Matrix/Cytoskeleton-relatedproteins
Sterile alpha motif domain containing 4, SAMD4 Hs. 98 259 14q22 22
Dual-speciﬁcity tyrosine-(Y)-phosphorylation-regulated kinase 4 Hs. 439 530 12p13 33
Myosin light polypeptide kinase, MYLK Hs. 386 078 3q21 10
Transmembrane 4 superfamily member 2, TM4SF2 Hs. 439 586 Xp11 34
Lysyl oxidase-like 2, LOXL2 Hs. 83 354 8p21 37
Dicer1, Dcr-1 homolog, DICER1 Hs. 87 889 14q32 34
∗Expression is presented as a % of the expression by vector-transfected control cells.
region decreased expression of genes with a role in diﬀer-
entiation or development. In contrast, the eﬀects of the
distal 33–173 residue portion of the molecule were no-
table in regard to expression of genes for MHC I proteins,
proteasome function, cell-cell interaction, arachidonic
acid metabolism, nuclear proteins, and cell-matrix and
cytoskeleton-related proteins (Table 2). Multiple genes
from the same pathway were frequently regulated in a
coordinated fashion. The HLA genes and proteasomal
subunit genes PSMB8 and PSMN9 represent such a set,
since the proteasome prepares short peptides for anti-
gen presentation on MHC-1. Similarly, GLG1, the TGF-
beta complex protein, and cadherins all participate in
the TGF-beta pathway. In some cases, amino-terminal
PTHrP and distal PTHrP appeared to act on related func-
tional pathways. The eﬀects of the amino-terminal and
carboxy-terminal domains on AKR enzymes and on pro-
teins with a role in arachidonic acid pathways exemplify
this situation. The enzymes upregulated by PTHrP 1-173
are involved in prostaglandin metabolism [30], while in
the PTHrP 33-173-regulated group, glutathione peroxi-
dases 1 and 3 inhibit 12-lipoxygenase and, to a lesser de-
gree 5-lipoxygenase [31, 32]. In addition, amino-terminal
PTHrP and distal PTHrP both have eﬀects on several
cell-matrixandcytoskeletongenes,althoughtheproximal
sequences upregulate expression and the distal sequences
decrease expression.
Exogenous PTHrP peptides do have biologic actions
in wild-type DU 145 cells. For example, we have eval-
uated their eﬀects on staurosporine-induced apoptosis.
PTHrP140-173 peptide treatment decreased caspases-3
and -9 activities and nuclear condensation compared to
vehicle treated cells. No signiﬁcant eﬀects on nuclear
condensation and caspases-3 or -9 were observed with
treatment with PTHrP 1-34 or scrambled PTHrP 140-
173 peptide [32]. Since protective eﬀects on apoptosis360 I. Tsigelny et al 2005:4 (2005)
were not observed for PTHrP 1-34, the human-speciﬁc
140-173 region appears responsible for the antiapoptotic
properties of PTHrP in prostate cancer cells through a
paracrine mechanism. These results would be consis-
tent with eﬀects mediated by transfection with either the
PTHrP 1-173 or the PTHrP 33-173 construct.
The genes aﬀected by PTHrP 1-173 and PTHrP 33-
173c ouldha v evariableeﬀectsonprostatecarcinomapro-
gression or metastasis. In several instances, both PTHrP
formshadactionsthatcouldretardcancergrowth.Forex-
ample, the apoptosis genes upregulated by PTHrP 1-173
only were generally proapoptotic and could conceivably
promote prostate cancer cell death. There are a number of
precedents for apoptosis sensitization by amino-terminal
PTHrP. PTHrP 1-32 induces or augments apoptosis in
human embryonic kidney (HEK) 293 cells [33], postcon-
ﬂuent mesenchymal cells [34], and lung alveolar type II
cells [12]. Just as apoptosis enhancement would slow tu-
mor growth, the eﬀects of carboxy-terminal PTHrP on
HLA class I expression and proteasomal function could
hinder carcinoma progression. Many prostate cancer cells
and other cancer cells downregulate MHC antigens, pre-
sumably as a mechanism of avoiding immune surveil-
lance [35, 36]. HLA class I antigen expression decreases
in more invasive prostate carcinomas and expression is
directly related to patient survival [37]. By upregulating
these molecules, PTHrP 33-173 expression could improve
the ability of CD8 T cells to detect and kill prostate tumor
cells [36]. Finally, increased expression of the glutathione
peroxidase enzymes mediated by distal PTHrP sequences
could negatively inﬂuence prostate tumor growth. By in-
hibiting 5- and 12-lipoxygenase, GPX1 would reduce can-
cer cell levels of 5-HETE and 12-HETE, mediators that
promote survival, growth, and invasiveness of prostate
cancer cells [38, 39, 40]. On the other hand, increased
expression of the AKR enzymes could augment prostate
cancergrowth. AKRC13 couldlimit production of PPARγ
ligands arising from PGJ2 by favoring PGF2α, rather than
PGJ2, production from PGD2. Decreasing these ligands
could support tumor progression because PPARγ has an-
tiproliferative eﬀects in prostate cancer cells and pro-
motes cell death [41, 42]. It should be noted that up-
regulation of the AKR enzymes could also be signiﬁ-
cant in prostate cancer in terms of eﬀects on androgen
levels. The AKR1C isoforms are involved in inactivat-
ing male and female sex hormones [43]. For example,
they catalyze the conversion of 5α-dihydrotestosterone to
5α-androstane-3α,1 7 β-diol, a much less potent andro-
gen [44], thereby regulating occupancy and activation
of the androgen receptor. Increased expression of E-
cadherin and P-cadherin would also favor prostate carci-
noma growth. E-cadherin has a positive relationship with
tumor invasiveness. Thus, the diﬀerentially expressed
genes regulated by PTHrP may either stimulate or re-
tard cancer progression. The overall eﬀect of amino- and
non-amino-terminal PTHrP on the pathophysiology of
prostate cancer will require direct experimental evalua-
tion.
The changes in gene expression induced by PTHrP
were notable for including several coherent expression
clusters, including the AKR enzymes on chromosome
10p15, the HLA class I antigens and proteasomal pathway
proteins on chromosome 6p21 and the E-cadherin/P-
cadherin pair on chromosome 16q22. These ﬁndings are
not unusual because genes with similar functions tend
to occur in adjacent positions along chromosomes. For
example, the individual members of pairs of adjacent
yeast genes shared the same functional category in 387
of 2018 pairs (19%), signiﬁcantly more than would be
expected by chance [45]. Clustering of genes with organ-
speciﬁc function has been observed in humans, as well
[46]. Chromosomal clustering of diﬀerentially expressed
genes could result from either genomic changes or tran-
scriptional mechanisms. In our experiments involving
transduction with a single gene, widespread genomic
changes are unlikely and transcriptional control is a more
probable explanation for regionally coherent changes in
expression patterns. This control could take the form
of common responses to transcription factors among
functionally similar genes. As an example, E-cadherin
and P-cadherin have homology in their 5 -promoter re-
gions, which are both recognized by Sp1-related nuclear
factors [47]. Similarly, expression of HLA class I genes
is mediated by conserved cis-acting regulatory elements,
including the enhancer A, the ISRE module, and the SXY
module [48]. Alternatively, coherent expression clus-
ters could arise from epigenetic mechanisms involving
changes in chromatin structure. Thus, histone deacetylase
inhibitors have been shown to enhance expression of
MHC class I antigens in tumor cells [49].
The observation that non-amino-terminal PTHrP
caused diﬀerential expression of many more genes than
amino-terminal PTHrP was somewhat unexpected. The
result is understandable, however, given the multifunc-
tional nature of PTHrP. Genes regulated solely by PTHrP
1-173 and not PTHrP 33-173 are under the control of
paracrine interactions of PTHrP 1-32 with its recep-
tor. In contrast, genes regulated by PTHrP 33-173 may
be aﬀected by paracrine interactions with any of the
downstream biologically active portions of the PTHrP
molecule, as well as intracrine mechanisms. Furthermore,
the eﬀect of PTHrP 33-173 transfection on expression of
DICER1 could be an additional explanation for the aug-
mented number of diﬀerentially expressed genes. Dicer is
an RNase that produces RNAi activity. Depletion of Dicer
reduces such activity in drosophila cells, while Ce l e g a n s
lacking functional Dicer are impaired in RNAi-mediated
gene suppression [50, 51]. Thus, a reduction in Dicer
expression after PTHrP 33-173 transduction in prostate
cancer cells could contribute to a general increase in gene
expression by reducing RNAi activity.
Our studies introduce a novel method to identify ef-
fects of PTHrP that are speciﬁc to functional peptide
domains contained within this polypeptide. Our results
show that PTHrP can exert nonoverlapping biological
eﬀects in prostate carcinoma cells that are attributable2005:4 (2005) PTHrP and Diﬀerential Gene Expression in Prostate Cancer 361
to amino-terminal and non-amino-terminal domains.
Amino-terminal PTHrP regulated groups of genes in-
volved in growth/apoptosis, prostaglandin and andro-
gen steroid metabolism, cell-matrix interactions, and de-
velopment/diﬀerentiation. Large changes were seen in
aldo-keto reductase genes that could play a role andro-
gen response. On the other hand, PTHrP 33-173 eﬀects
were signiﬁcant for increases in expression of HLA class
I antigens and the proteasomal proteins that could be
involved in antigen presentation. These changes could
render prostate carcinoma cells more susceptible to im-
mune surveillance and might constitute a rationale for
a PTHrP-based therapy for prostate cancer. Finally, our
work has identiﬁed coherent expression clusters, chromo-
somal regions of increased diﬀerential gene expression af-
ter PTHrP transduction. Two interesting clusters involved
the aldo-keto reductase genes on chromosome 10p15 and
the HLA genes on chromosome 6p21. Comparing mi-
croarray analysis results from cells transduced with dif-
ferent forms of a regulatory protein provides a mecha-
nism for elucidating domain-speciﬁc eﬀects in gene ex-
pression. Further application of this novel approach to
microarray analysis with other PTHrP species can help to
elucidate the complex eﬀects that PTHrP exerts on cancer
cells.
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